Unveiling Dupixent: Exploring Side Effects and Safety Considerations

Warnings

There are some important warnings associated with Dupixent (dupilumab). Hypersensitivity reactions, including anaphylaxis and other allergic symptoms, have been reported. If you experience any signs of an allergic reaction, such as rash, swelling, or difficulty breathing, seek immediate medical attention.

Dupixent eczema may cause conjunctivitis and keratitis, so it’s important to report any new or worsening eye symptoms to your healthcare provider. It may also increase the risk of developing eosinophilic conditions, so inform your doctor if you experience a red or purple rash, shortness of breath, or nerve pain in your hands or feet.

Your healthcare provider will determine whether you should continue using oral, topical, or inhaled corticosteroids alongside sanofi Dupixent for asthma. These medications should be gradually reduced and not discontinued without your doctor’s advice. Additionally, if you develop new joint pain or swelling, further investigation may be necessary.

Before initiating sanofi Dupixent (dupilumab), any pre-existing worm or parasitic infections should be treated. If you become infected during treatment and do not respond to antihelminths, Dupixent should be discontinued until the infection resolves.

It is important to avoid the use of live vaccines while using Dupixent eczema, as it may reduce the immune response to other vaccinations.

The safety and effectiveness of sanofi Dupixent medication in certain age groups have not been established. Consult your doctor regarding its use in children under 6 months of age for atopic dermatitis, under 6 years of age for asthma, under 18 years of age for chronic rhinosinusitis with nasal polyposis, under 1 year of age or weighing less than 33 pounds (15 kg) for eosinophilic esophagitis, and under 18 years of age for prurigo nodularis.

If you are pregnant or planning to become pregnant, the potential risks of using Dupixent eczema during pregnancy are not known. There is a pregnancy exposure registry available for women using Dupixent during pregnancy, and you can enroll in this registry or obtain more information by contacting the provided phone number or visiting the URL mentioned.

The passage of dupixent atopic dermatitis into breast milk is uncertain, so caution is advised if you are breastfeeding.